topic

546 The FSTL1-DIP2A axis as a promising target in the anti-PD1 therapy of advanced gastric cancer
Chie Kudo-Saito, Narikazu Boku, Hirokazu Shoji, Hiroshi Imazeki, Kengo Nagashima, Kai Tsugaru, Naoki Takahashi, Takeshi Kawakami, Yusuke Amanuma, Takeru Wakatsuki, Naohiro Okano, Yukiya Narita, Yoshiyuki Yamamoto, Rika Kizawa, Kazunori Aoki, Kei Muro

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A620; DOI: 10.1136/jitc-2023-SITC2023.0546
547 Reprogramming of type I interferon-responding tumor-reactive T lymphocytes associates with improved outcomes to neoadjuvant doublet immunotherapy in HNSCC
Housaiyin Li, Patricia Santos, Aditi Kulkarni, Brian Isett, Joy Marion, Simon Chiosea, Uma Duvvuri, Seungwon Kim, Mark Kubik, Dan P Zandberg, Riyue Bao, Lazar Vujanovic, Robert Ferris

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A621; DOI: 10.1136/jitc-2023-SITC2023.0547
548 Evolution of myeloid-mediated mechanisms of immunotherapy resistance at single-cell resolution with human prostate cancer progression
Aram Lyu, Zenghua Fan, Diamond Luong, Ali Setayesh, Alec Starzinski, Eliezer Van Allen, Lawrence Fong

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A622; DOI: 10.1136/jitc-2023-SITC2023.0548
549 Multiomics biomarker analysis in 12 mouse syngeneic models under ICI treatment
Binchen Mao, Sheng Guo

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A623; DOI: 10.1136/jitc-2023-SITC2023.0549
550 Harnessing natural IL-18 activity through IL-18BP blockade reshapes the tumor microenvironment for potent anti-tumor immune response
Assaf Menachem, Zoya Alteber, Gady Cojocaru, Tal Fridman Kfir, Dan Blat, Olga Leiderman, Moran Galperin, Lital Sever, Nadav Cohen, Keren Cohen, Roy Granit, Sandra Vols, Masha Frenkel, Lior Faigenbloom, Liron Soffer, Karin Meyer, Keren Menachem, Hadas Galon Tilleman, Michal Perpinial, Evgeny Tatirovsky, Pierre Ferre, Eran Ophir

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A624-A628; DOI: 10.1136/jitc-2023-SITC2023.0550
551 Overcoming immune resistance in MMRd tumors
Guillaume Mestrallet

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A629; DOI: 10.1136/jitc-2023-SITC2023.0551
552 Tumor-infiltrating neutrophils associate with resistance to anti-PD1 immunotherapy in NSCLC
Shucheng Miao, B Leticia Rodriguez, Jessica M Konen, Yanhua Tian, Don Gibbons

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A630; DOI: 10.1136/jitc-2023-SITC2023.0552
553 Increased efficacy of cetuximab after pembrolizumab failure in cutaneous squamous cell carcinoma
Renee Morecroft, Jordan Phillipps, George Ansstas

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A631; DOI: 10.1136/jitc-2023-SITC2023.0553
554 Clinical outcomes of patients treated with immune checkpoint inhibitor therapy for early-stage melanoma recurrence: a retrospective cohort study
Nga Nguyen, Guihong Wan, Hannah Rashdan, Bonnie W Leung, Jordan Phillips, Boshen Yan, Ahmad Rajesh, Michael R Collier, Kimberly Tang, Min Seok Choi, Nora A Alexander, Ruple Jairath, Shawn Kwatra, Mia S DeSimone, Yevgeniy R Semenov

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A632-A633; DOI: 10.1136/jitc-2023-SITC2023.0554
555 Challenges in predicting ICI response in HPV+ HNSCC: insights into the tumor microenvironment
Anastasiia Nikitina, Anastasia Sobol, Evgeniia Alekseeva, Andrey Tyshevich, Anna Love, Adam J Luginbuhl, Alban J Linnenbach, Joseph M Curry, Vladimir Kushnarev, Christopher JH Davitt, Nikita Kotlov, Alexander Bagaev, Nathan Fowler

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A634; DOI: 10.1136/jitc-2023-SITC2023.0555

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages